Tumor mutational load predicts survival after immunotherapy across multiple cancer types

Nature Genetics, Год журнала: 2019, Номер 51(2), С. 202 - 206

Опубликована: Янв. 8, 2019

Язык: Английский

---

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic

Annals of Oncology, Год журнала: 2018, Номер 30(1), С. 44 - 56

Опубликована: Ноя. 1, 2018

Treatment with immune checkpoint blockade (ICB) agents such as anti-programmed cell death protein 1 (PD-1), death-ligand (PD-L1), and/or anti-cytotoxic T-lymphocyte-associated 4 (CTLA-4) can result in impressive response rates and durable disease remission but only a subset of patients cancer. Expression PD-L1 has demonstrated utility selecting for to ICB proven be an important biomarker patient selection. Tumor mutation burden (TMB) is emerging potential biomarker. However, refinement interpretation contextualization required.

Язык: Английский

---

The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy

Nature reviews. Cancer, Год журнала: 2019, Номер 19(3), С. 133 - 150

Опубликована: Фев. 12, 2019

Язык: Английский

---

Roles of the immune system in cancer: from tumor initiation to metastatic progression

Genes & Development, Год журнала: 2018, Номер 32(19-20), С. 1267 - 1284

Опубликована: Окт. 1, 2018

The presence of inflammatory immune cells in human tumors raises a fundamental question oncology: How do cancer avoid the destruction by attack? In principle, tumor development can be controlled cytotoxic innate and adaptive cells; however, as develops from neoplastic tissue to clinically detectable tumors, evolve different mechanisms that mimic peripheral tolerance order tumoricidal attack. Here, we provide an update recent accomplishments, unifying concepts, future challenges study tumor-associated cells, with emphasis on metastatic carcinomas.

Язык: Английский

---

Tumour-intrinsic resistance to immune checkpoint blockade

Nature reviews. Immunology, Год журнала: 2019, Номер 20(1), С. 25 - 39

Опубликована: Сен. 30, 2019

Язык: Английский

---

Therapeutic cancer vaccines

Nature reviews. Cancer, Год журнала: 2021, Номер 21(6), С. 360 - 378

Опубликована: Апрель 27, 2021

Язык: Английский

---

Hallmarks of response, resistance, and toxicity to immune checkpoint blockade

Cell, Год журнала: 2021, Номер 184(21), С. 5309 - 5337

Опубликована: Окт. 1, 2021

Язык: Английский

---

Conserved pan-cancer microenvironment subtypes predict response to immunotherapy

Cancer Cell, Год журнала: 2021, Номер 39(6), С. 845 - 865.e7

Опубликована: Май 20, 2021

Язык: Английский

---

The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker

Cancer Cell, Год журнала: 2020, Номер 39(2), С. 154 - 173

Опубликована: Окт. 30, 2020

Язык: Английский

---

Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma

Nature Medicine, Год журнала: 2019, Номер 25(3), С. 462 - 469

Опубликована: Фев. 11, 2019

Язык: Английский

---